Skip to main content
Premium Trial:

Request an Annual Quote

MetaSight Diagnostics, Maccabi's KSM Partner for Large-Scale Metabolomics Research Study in Israel

NEW YORK – MetaSight Diagnostics, an Israeli health technology company developing liquid biopsy tests for the early detection of chronic and acute diseases, said on Tuesday that it has inked a partnership with Kahn-Sagol-Maccabi (KSM), the research and innovation center of Israel's HMO Maccabi Health Services, to support the creation of a comprehensive metabolomics dataset consisting of hundreds of thousands of de-identified serum samples.

The company's goal is to advance a liquid biopsy platform for both oncology and other disease areas, with early development targets in chronic liver disease, cancer, cardiovascular disease, and neurological diseases.

MetaSight Founder and CEO Tomer Shlomi said in a statement that the firm's proprietary high-throughput mass spectrometry approach — using liquid chromatography and mass spectrometry instruments and consumables from Thermo Fisher Scientific — has enabled the firm to generate what it believes is the world’s largest serum molecular dataset. In addition to metabolomics, the company is also building datasets in lipidomics and proteomics.

Financial terms of the collaboration were not disclosed.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.